A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer

Research output: Contribution to journalArticle

Abstract

Screening for genes or markers relevant to bladder cancer (BC) tumorigenesis and progression is of vital clinical significance. The present study used reverse-transcription quantitative PCR reaction assays to examine the expression of mRNA encoding Rho GTPase-activating protein 9 (ARHGAP9) in BC tissue samples and to determine whether ARHGAP9 is an independent prognostic biomarker for non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). The results revealed that the downregulation of ARHGAP9 expression in the tissue of patients with NMIBC or MIBC was significantly associated with a poor prognosis. In patients with NMIBC, a high expression of ARHGAP9 was significantly associated with prolonged recurrence-free survival, whereas in MIBC patients, it was significantly associated with an increased progression-free and cancer-specific survival. The risk of cancer-specific death was 2.923 times higher (95% confidence interval, 1.192-7.163) when ARHGAP9 levels were decreased. In conclusion, lower expressions of ARHGAP9 correlated with BC prognosis, indicating that it may be a useful marker for guiding treatment application.

Original languageEnglish (US)
Pages (from-to)476-486
Number of pages11
JournalOncology Letters
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

Tumor Suppressor Genes
Urinary Bladder Neoplasms
Biomarkers
Muscle Neoplasms
Muscles
Survival
Reverse Transcription
Neoplasms
Carcinogenesis
Down-Regulation
Confidence Intervals
Recurrence
Polymerase Chain Reaction
Messenger RNA
Genes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • Muscle invasive bladder cancer
  • Non-muscle invasive bladder cancer
  • Progression
  • Recurrence
  • Rho GTPase-activating protein 9

Cite this

@article{e0c83191d2d34d929f848b91d73cd722,
title = "A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer",
abstract = "Screening for genes or markers relevant to bladder cancer (BC) tumorigenesis and progression is of vital clinical significance. The present study used reverse-transcription quantitative PCR reaction assays to examine the expression of mRNA encoding Rho GTPase-activating protein 9 (ARHGAP9) in BC tissue samples and to determine whether ARHGAP9 is an independent prognostic biomarker for non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). The results revealed that the downregulation of ARHGAP9 expression in the tissue of patients with NMIBC or MIBC was significantly associated with a poor prognosis. In patients with NMIBC, a high expression of ARHGAP9 was significantly associated with prolonged recurrence-free survival, whereas in MIBC patients, it was significantly associated with an increased progression-free and cancer-specific survival. The risk of cancer-specific death was 2.923 times higher (95{\%} confidence interval, 1.192-7.163) when ARHGAP9 levels were decreased. In conclusion, lower expressions of ARHGAP9 correlated with BC prognosis, indicating that it may be a useful marker for guiding treatment application.",
keywords = "Muscle invasive bladder cancer, Non-muscle invasive bladder cancer, Progression, Recurrence, Rho GTPase-activating protein 9",
author = "Kim, {Isaac Y.}",
year = "2020",
month = "1",
day = "1",
doi = "https://doi.org/10.3892/ol.2019.11123",
language = "English (US)",
volume = "19",
pages = "476--486",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "1",

}

A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. / Kim, Isaac Y.

In: Oncology Letters, Vol. 19, No. 1, 01.01.2020, p. 476-486.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer

AU - Kim, Isaac Y.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Screening for genes or markers relevant to bladder cancer (BC) tumorigenesis and progression is of vital clinical significance. The present study used reverse-transcription quantitative PCR reaction assays to examine the expression of mRNA encoding Rho GTPase-activating protein 9 (ARHGAP9) in BC tissue samples and to determine whether ARHGAP9 is an independent prognostic biomarker for non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). The results revealed that the downregulation of ARHGAP9 expression in the tissue of patients with NMIBC or MIBC was significantly associated with a poor prognosis. In patients with NMIBC, a high expression of ARHGAP9 was significantly associated with prolonged recurrence-free survival, whereas in MIBC patients, it was significantly associated with an increased progression-free and cancer-specific survival. The risk of cancer-specific death was 2.923 times higher (95% confidence interval, 1.192-7.163) when ARHGAP9 levels were decreased. In conclusion, lower expressions of ARHGAP9 correlated with BC prognosis, indicating that it may be a useful marker for guiding treatment application.

AB - Screening for genes or markers relevant to bladder cancer (BC) tumorigenesis and progression is of vital clinical significance. The present study used reverse-transcription quantitative PCR reaction assays to examine the expression of mRNA encoding Rho GTPase-activating protein 9 (ARHGAP9) in BC tissue samples and to determine whether ARHGAP9 is an independent prognostic biomarker for non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). The results revealed that the downregulation of ARHGAP9 expression in the tissue of patients with NMIBC or MIBC was significantly associated with a poor prognosis. In patients with NMIBC, a high expression of ARHGAP9 was significantly associated with prolonged recurrence-free survival, whereas in MIBC patients, it was significantly associated with an increased progression-free and cancer-specific survival. The risk of cancer-specific death was 2.923 times higher (95% confidence interval, 1.192-7.163) when ARHGAP9 levels were decreased. In conclusion, lower expressions of ARHGAP9 correlated with BC prognosis, indicating that it may be a useful marker for guiding treatment application.

KW - Muscle invasive bladder cancer

KW - Non-muscle invasive bladder cancer

KW - Progression

KW - Recurrence

KW - Rho GTPase-activating protein 9

UR - http://www.scopus.com/inward/record.url?scp=85077212068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077212068&partnerID=8YFLogxK

U2 - https://doi.org/10.3892/ol.2019.11123

DO - https://doi.org/10.3892/ol.2019.11123

M3 - Article

VL - 19

SP - 476

EP - 486

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 1

ER -